Bristol-Myers Squibb Company (BRM) Fair Value & Analysis
Healthcare · DE · Market cap €107B · ISIN US1101221083
What is Bristol-Myers Squibb Company really worth?
A strong business, trading 11% below our fair value of €64.94.
As of Aug 22, 2026, the fair value of Bristol-Myers Squibb Company is €64.94 per share against a price of €57.62, so the fair value sits 13% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
For context
Fair value as of: Aug 22, 2026
From 26 valuation models · updated 15 days ago
Fair value updated Aug 22, 2026, revised from €75.99 to €64.94 (−14.5%) since Aug 13, 2026. Share price +4.7% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A fairly wide model range (€42.48 to €81.18) leaves room in how you read the outcome.
- The price sits in the lower half of our model range, the side with the larger margin of safety.
- The data supports the verdict: every model runs on fully documented inputs.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range €33.30 – €68.44 · fair‑value band €42.48 – €81.18 · the €57.62 price screens below the €64.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.
Analysis
Bristol-Myers Squibb Company (BRM) currently trades at €57.62, while our model-based Fair Value estimate is €64.94, implying the stock looks roughly 11.3% undervalued today. The Quality Score stands at 78/100 (high quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of €71.70 per share, and 17 of the 26 models we run sit above the €57.62 price. Bear case: the Earnings-Based group reads lowest at €20.03, and 9 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Bristol-Myers Squibb Company generated revenue of €48.5B at a net margin of 15.0%. Revenue grew 2.6% year over year. It earns a return on equity of 38.7%. Net debt stands at €36.9B. Fundamentals as of Aug 22, 2026
Our scenario range runs from €42.48 (bear case) to €81.18 (bull case); at €57.62, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 61% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −18% fair-value upside, at 13%, BRM screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly €0.4298 per share, which is 0.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (€71.70) versus Asset-Based (€6.06). Highest evidence: FCF DCF (79).
Notify me when BRM reaches fair value
Put BRM on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 83
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience.
Full company description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bristol-Myers Squibb Company reported revenue of $48.2B in FY2025 versus $46.4B in FY2021, a compound +1.0%/yr. Reported net income was $7.1B in FY2025, compounding +0.2%/yr from FY2021.
of which total revenue +11.6 % · buybacks/dilution −2.3 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch BRM: get an alert when its fair value changes →
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,176 | $389.47 | −67% |
| Johnson & Johnson, JNJ | $275.23 | $169.04 | −39% |
| AbbVie Inc ABBV | $256.46 | $67.72 | −74% |
| Roche Holding RO | CHF 374.60 | CHF 306.54 | −18% |
| Merck & Co MRK | €131.98 | €101.38 | −23% |
| Novartis AG NOVN | CHF 123.74 | CHF 114.90 | −7% |
| Novo Nordisk A/S NOVOB | kr 295.50 | kr 409.46 | +39% |
| Amgen Inc AMGN | $437.23 | $252.02 | −42% |
| Gilead Sciences, Inc GILD | $151.00 | $146.50 | −3% |
| Pfizer Inc PFE | $28.02 | $24.87 | −11% |
Compare Bristol-Myers Squibb Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Bristol-Myers Squibb Company (BRM) overvalued or undervalued?
What is the fair value of BRM?
What is the quality score of BRM?
What is the price target for Bristol-Myers Squibb Company (BRM)?
What is the Bristol-Myers Squibb Company stock forecast for 2026?
What is the revenue of Bristol-Myers Squibb Company (BRM)?
What is the net profit margin of BRM?
Does Bristol-Myers Squibb Company pay a dividend?
Watch Bristol-Myers Squibb Company in the live analysis
One click puts Bristol-Myers Squibb Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.